Global AI in Medical Imaging Horizon: Forecasts, Competitive Architecture, and Reimbursement-Driven Monetization, 2024A-2035E

This report provides a global analysis of artificial intelligence in medical imaging from 2024A to 2035E, covering market sizing, segment forecasts, reimbursement-driven monetization, competitive architecture, regulatory and evidence trends, and strategic implications for vendors, providers and investors. It is the 2026 edition of the Markintel® AI in Medical Imaging Horizon series.

The report evaluates how AI is being commercialized across CT, MRI, X-ray and digital radiography, mammography and DBT, ultrasound, nuclear imaging and PET, and how value is shifting from stand-alone algorithms toward workflow integration, reimbursement maturity, enterprise deployment, cloud and pay-per-use economics, and recurring software models.

Most studies of this market concentrate on regulatory clearance counts or vendor lists. This report centers on monetization. It explains why AI tools with similar technical or regulatory profiles can monetize very differently depending on payer coverage, workflow integration, clinical evidence, procurement model, buyer type and enterprise deployment path.

Key Questions Answered

• How is the global medical imaging AI market structured by modality, clinical area, application, technology layer, revenue stream, end user and region?
• Which AI imaging categories have the strongest monetization potential through 2035E?
• How does reimbursement shape adoption, pricing and defensibility, and what moves a use case into a mature reimbursed tier?
• Where do cloud and pay-per-use models gain ground against installed and hardware-embedded AI?
• How are foundation models and multi-condition platforms changing the position of single-indication vendors?
• Which OEMs, enterprise imaging platforms, AI-native vendors, provider networks and cloud providers control the commercial layers that matter most?

Market Snapshot

The report is built around a reconciled 2024A-2035E market model covering the major commercial dimensions of medical imaging AI: modality, clinical area, clinical application, technology layer, revenue stream, end-user organization, geography and reimbursement tier. Base, Bull and Bear scenarios and sensitivity cases frame the outlook.

Growth in the base case is shaped by reimbursement expansion, enterprise platform adoption, AI-enabled productivity, cloud deployment and disease-specific quantitative analytics. A reimbursement-tier framework separates mature reimbursed AI, developing reimbursement categories, non-reimbursed productivity AI, and hardware-embedded or out-of-tier AI, because each monetizes through a different budget.

Key Market Trends

1. Advantage is shifting from model novelty to workflow control. The best-positioned assets own workflow, evidence, reimbursement documentation or governance in the imaging value chain.
2. The reimbursement tier is the central structural change. It separates AI that can be billed as a clinical service from AI that must monetize through productivity, scanner attach or enterprise software budgets. Cardiac CT analytics shows how payment policy reshapes a category.
3. Foundation models are compressing single-indication vendors. Multi-condition triage and foundation-model platforms put pressure on narrow products and accelerate consolidation.
4. Enterprise platforms and provider networks consolidate control. Enterprise imaging and PACS vendors, provider-owned AI networks and reimbursed quantitative specialists gain influence over which algorithms are deployed and paid for.
5. Cloud and pay-per-use models expand. Their growth changes how vendors price, deploy and govern AI alongside installed enterprise software.
6. Evidence and governance become buying criteria. Screening evidence in mammography, AI monitoring, and regulatory regimes from FDA PCCP to the EU AI Act increasingly shape procurement.

Competitive Structure

The report analyzes competition across the main AI imaging control points: imaging OEMs; enterprise imaging and PACS, RIS and VNA platforms; AI-native clinical platforms; reimbursed quantitative analytics companies; breast and oncology AI vendors; reconstruction and acquisition AI companies; reporting and workflow automation vendors; AI orchestration and governance platforms; cloud infrastructure providers; and provider-network AI platforms. M&A and partnership implications are assessed for each.

Companies discussed include GE HealthCare, Siemens Healthineers, Philips, Canon Medical, Fujifilm, United Imaging, Pro Medicus, Sectra, Intelerad, Agfa HealthCare, Aidoc, Viz.ai, RapidAI, Qure.ai, Annalise.ai, DeepHealth / RadNet, HeartFlow, Cleerly, Elucid, Circle Cardiovascular Imaging, Lunit, iCAD, ScreenPoint, Hologic, Vara, Rad AI, Microsoft / Nuance, deepc, CARPL.ai, Ferrum Health, Blackford, Incepto, AWS, Microsoft Azure, Google Cloud and NVIDIA.

What's Inside

Global market model, 2024A-2035E: TAM, SAM and expected-market framing, with Base, Bull, Bear and sensitivity scenarios.

Segment forecasts: By region, modality, clinical area, clinical application, revenue stream, technology layer, end-user organization and reimbursement tier.

Reimbursement and regulation: Payment policy implications, cardiac CT reimbursement and quantitative analytics, mammography evidence pathways, and FDA, De Novo, Breakthrough Device, PCCP, EU AI Act and MDR, NMPA and PMDA considerations.

Enterprise and platform economics: Enterprise imaging, PACS, reporting, orchestration and AI governance; foundation-model and multi-condition AI strategy; and cloud, pay-per-use and enterprise software monetization.

Provider economics: Provider-owned AI networks, teleradiology and outpatient imaging economics.

Strategy: Competitive positioning, M&A and partnership implications, and execution playbooks by stakeholder type.

Who Should Read This Report

• Imaging OEM and enterprise imaging executives and product leaders
• AI-native imaging vendors and reporting and workflow software companies
• Provider networks, imaging centers, radiology groups and teleradiology operators
• Cloud and infrastructure providers serving imaging
• Corporate strategy, corporate development and M&A teams
• Investors, private equity and advisory firms

Why This Report

Use the report to evaluate the size and structure of the medical imaging AI market, identify the categories with the strongest monetization potential, understand how reimbursement affects adoption and pricing, compare opportunity across modalities, clinical areas and technology layers, benchmark competitive positioning, and assess M&A, partnership and market-entry options. It supports strategy, corporate development, investment, product planning and go-to-market decisions.